684 patents
Page 5 of 35
Utility
Heavy Chain Antibodies Binding to Psma
3 Aug 23
Anti-PSMA heavy chain antibodies (e.g., UniAbs™) are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by the expression of PSMA.
Wim van Schooten, Starlynn Clarke, Kevin Dang, Ben Buelow
Filed: 3 Feb 23
Utility
Cyclopropyl Dihydroquinoline Sulfonamide Compounds
27 Jul 23
BENJAMIN C. MILGRAM, ISSAC E. MARX, JOHN STELLWAGEN, WEI ZHAO, ALAN H. CHERNEY
Filed: 10 Jun 21
Utility
Fc-Containing Molecules Exhibiting Predictable, Consistent, and Reproducible Glycoform Profiles
27 Jul 23
Zhimei DU, Pranhitha REDDY, Randal B. BASS, Feng HE, William C. FANSLOW, III, Yuling ZHANG, Da REN, Randall R. KETCHEM
Filed: 14 Jul 22
Utility
Treatment of Pediatric Acute Lymphoblastic Leukemia
27 Jul 23
The present invention relates to a method for the treatment, amelioration or elimination of pediatric acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19×CD3 bispecific single chain antibody construct to a pediatric ALL patient in the need thereof.
Gerhard Zugmaier
Filed: 16 Sep 22
Utility
PCSK9 Inhibitors and Methods of Use Thereof to Treat Cholesterol-related Disorders
27 Jul 23
Methods of lowering LDL cholesterol in a pediatric subject having a cholesterol-related disorder, e.g., heterozygous familial hypercholesterolemia (HeFH), by administering a PCSK9 inhibitor are provided.
Andrew W. Hamer, Ian Matthew Bridges, Huei Wang, Andrea Ruzza, Christopher Kurtz
Filed: 27 May 21
Utility
Heteroalkyl Dihydroquinoline Sulfonamide Compounds
20 Jul 23
The present invention provides heteroalkyl dihydroquinoline sulfonamide compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7.
BENJAMIN C. MILGRAM, GWENAELLA RESCOURIO
Filed: 11 Jun 21
Utility
Low-viscosity, High Concentration Evolocumab Formulations and Methods of Making the Same
20 Jul 23
Provided herein are formulations of PCSK9-binding polypeptides, such as those comprising evolocumab, that comprise N-acetyl arginine and have reduced viscosities when compared to formulations lacking N-acetyl arginine.
Christopher James SLOEY, Sekhar KANAPURAM, Huanchun CUI, Chio Mui CHAN, Elaheh BINABAJI
Filed: 23 Aug 22
Utility
Mammalian Cell Culture
20 Jul 23
The invention provides a method for culturing mammalian cells.
Brian D. FOLLSTAD, Rebecca E. McCOY, Arvia E. MORRIS
Filed: 8 Mar 23
Utility
Drug Injection Device with Visual and Audio Indicators
20 Jul 23
A drug injection device (10) including a housing (12) for holding a container (20) having a needle (24) for penetrating skin and a plunger (42) for expelling a drug stored in the container.
Peter V. Shultz, Christopher R. Folk, Sigrid Moeslinger, Masamichi Udagawa, Molly Evans, Lin Gao, Lisa Nugent
Filed: 23 Mar 23
Utility
Use of GDF15 for Treating Cardiometabolic Syndrome and Other Conditions
6 Jul 23
The present disclosure provides a method of treating cardiometabolic syndrome (CMS) with a GDF15 molecule.
Murielle Marie V. ELLISON, Clarence H. HALE, Xin LUO, Marina STOLINA
Filed: 2 Oct 20
Utility
Bispecific FC Molecules
6 Jul 23
Described herein is a bispecific molecule containing an Fc polypeptide chain and immunoglobulin variable regions.
Luis G. Borges, Patrick Baeuerle, Wei Yan, Mark L. Michaels
Filed: 17 Mar 22
Utility
Protease-activatable Bispecific Proteins
6 Jul 23
Described herein are protease-activatable proteins (PABPs), which, when activated, can mediate cytolysis of target cells by effector cells.
Wei Yan, Martin J. Pentony, Mark L. Michaels, Patrick Baeuerle
Filed: 22 Apr 22
Utility
Administration of an Anti-activin-a Compound to a Subject
29 Jun 23
The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor.
Huiquan HAN, Christopher Michael HAQQ, Isaac CIECHANOVER, Xiaolan ZHOU, John Zhao-Nian LU
Filed: 22 Dec 22
Utility
Tubing Support Device and Method of Manufacture
29 Jun 23
A tubing support device for tubing of a drug manufacturing system.
Kenneth Shoemaker, Jonathan Anson, Bret Wylie, Glenn M. Hunter, Sperry K. Brown
Filed: 25 May 21
Utility
Determination of Free N-terminus of Pegfilgrastim Using an Acid Protease
29 Jun 23
The present disclosure provides materials and methods for determining the presence of an N-terminal modification on a therapeutic protein, and/or the efficiency of N-terminal modification, such as PEGylation, at the N-terminus of a therapeutic protein such as Filgrastim (wherein the PEGylated version is therefore Pegfilgrastim).
Zhongqi Zhang, Bhavana Shah
Filed: 19 Mar 21
Utility
Methods of Treating Left Ventricle Hypertrophy
29 Jun 23
Disclosed are methods for treatment of a subject with left ventricle hypertrophy.
Rainer OBERBAUER, Bruno FOUQUERAY, Katharina DÖRR
Filed: 14 May 21
Utility
Systems and Methods for Remotely Processing Data Collected by a Drug Delivery Device
29 Jun 23
Systems and methods are disclosed for processing sensor data collected by a drug delivery device with an external computing device.
Adam B. McCullough, Basel Hasan Taha, Jimmie L. Ward, Christopher R. Folk, Steven William Badelt, Ferry Tamtoro, Huaying Yang, Mark Ka Lai Lee, Desheng Yin, Scott R. Gibson, Donald Busby, Peter V. Shultz, Keith P. Kogler
Filed: 17 Feb 23
Utility
Multispecific Heavy Chain Antibodies with Modified Heavy Chain Constant Regions
29 Jun 23
Katherine Harris, Ute Schellenberger, Omid Vafa, Nathan Trinklein, Wim Van Schoofen, Shelley Force Aldred, Duy Pham, Starlynn Clarke
Filed: 29 Apr 21
Utility
Bispecific Binding Constructs
29 Jun 23
New formats of bispecific binding constructs are described that bind to a target antigen and to a CD3 molecule on an effector cell, as well as their methods of making Additionally, uses in therapeutic indications are also described.
Pavan Ghattyvenkatakrishna, Brendan Amer
Filed: 3 Jun 21
Utility
Novel PRMT5 Inhibitors
25 May 23
Jennifer Rebecca ALLEN, Albert AMEGADZIE, Diane Jennifer BEYLKIN, Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Michael J. FROHN, Sanne Ormholt Schroder GLAD, Birgitte Weinreich HUSEMOEN, Matthew R. KALLER, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Qingyian LIU, Patricia LOPEZ, Vu Van MA, Francesco MANONI, Jose MEDINA, Ana Elena MINATTI, Jorge PEIRO CADAHIA, Liping PETTUS, Alexander J. PICKRELL, Ian SARVARY, Nuria A. TAMAYO, Mikkel VESTERGAARD
Filed: 11 Feb 21